Twitter

Posts Tagged ‘gmbh’


Apogenix Receives FDA Orphan Drug Designation For Apocept(TM) To Treat Myelodysplastic Syndromes And Initiates Clinical Phase I Study

Apogenix GmbH, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, announced today that its lead product, Apocept(TM) (APG101), has been granted orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of Myelodysplastic syndromes (MDS)…

Read More...

RBL001/RBL002 Phase I Clinical Trial

Condition :   Melanoma Intervention :   Biological: RBL001/RBL002 Sponsors :   Ribological GmbH;   Ribological GmbH Recruiting – verified September 2012

Read More...

Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma

Condition :   Advanced Melanoma Intervention :   Drug: dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus Sponsors :   University of Regensburg;   University of Regensburg;   ClinAssess GmbH Recruiting – verified June 2012

Read More...

Utilization of Doce Onkovis

Condition :   Carcinoma Intervention :   Sponsors :   Onkovis GmbH;   Onkovis GmbH;   AKP Freiburg GmbH (Clinical Research Organization) Recruiting – verified June 2012

Read More...

PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma

Condition :   Ewing Family of Tumors, Rhabdomyosarcoma Intervention :   Drug: Lipegfilgrastim Sponsors :   Teva Pharmaceutical Industries;   Merckle GmbH Not yet recruiting – verified April 2012

Read More...

Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)

Conditions :   Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer Interventions :   Drug: nab-Paclitaxel;   Drug: Paclitaxel Sponsors :   German Breast Group;   German Breast Group;   Celgene GmbH;   Roche Pharma AG Not yet recruiting – verified April 2012

Read More...

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Conditions :   Carcinoid Tumor of the Small Bowel;   Neuroendocrine Tumour Interventions :   Drug: Octreotide;   Drug: Octreotide;   Drug: 177Lu-DOTA0-Tyr3-Octreotate Sponsors :   Advanced Accelerator Applications;   Pierrel Research Europe GmbH Not yet recruiting – verified April 2012

Read More...

Photodynamic Therapy of Actinic Keratoses With Alacare®

Condition :   Actinic Keratosis Intervention :   Sponsor :   photonamic GmbH & Co. KG Not yet recruiting – verified April 2012

Read More...

Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML

Condition :   Acute Myeloid Leukemia Intervention :   Drug: clofarabine, cytarabine, idarubicin Sponsors :   Hannover Medical School;   Hannover Clinical Trial Center GmbH;   Genzyme Recruiting – verified February 2012

Read More...

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas

Conditions :   Gastric Adenocarcinoma With Peritoneal Carcinomatosis;   Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis;   Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis Interventions :   Drug: catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel;   Drug: Fluorouracil, leucovorin, oxaliplatin, docetaxel Sponsors :   AIO-Studien-gGmbH;   Fresenius Biotech GmbH Recruiting – verified January 2012

Read More...